Drug: SP01A              ClinicalTrials.gov Identifier:  NCT00113412

A Study of an Oral Entry Inhibitor, SP01A, in Treatment-Experienced
HIV-Infected Patients.  This study is currently recruiting patients.

One measurement of an HIV infected person's risk of progressing to AIDS is
the number of viral particles of HIV in their blood (called a "viral load").
In a previous phase I/II study, SP01A was observed to significantly lower
the amount of HIV in blood, improve quality of life (how well subject's
felt), have a favorable safety profile (minimal side effects), and be well
tolerated. Moreover, in in vitro testing SP01A: (1) demonstrated comparable
or greater efficacy than currently approved anti-HIV drugs in preventing HIV
virus replication; (2) was observed to have minimal toxic effect on human
cells; and (3) demonstrated significant efficacy in preventing virus
replication of HIV virus strains that resist currently approved anti-HIV
treatments. Based on these results, SP01A demonstrates promise as a new and
novel anti-HIV treatment.

The goal of this study is to further look at the dose response, efficacy,
and safety of SP01A as monotherapy, given as a capsule to be swallowed, in
the treatment of HIV-infected subjects. The investigators want to see if
SP01A will lower the amount of HIV in blood.
http://clinicaltrials.gov/ct/show/NCT00113412;jsessionid=EBDCC037D288A9314B0
95FA5761D487F?order=4

---------------------------------------------------------------------
Drug: CCR5mAb004          ClinicalTrials.gov identifier  NCT00114699

Safety and Efficacy of an Antibody to CCR5 in Individuals with HIV who Are
Not Currently on Antiretroviral Therapy.   This study is currently
recruiting patients.

This is a phase 1, randomized, placebo-controlled, dose-escalation study of
CCR5mAb004 in HIV-1 seropositive individuals who are not receiving
concurrent antiretroviral therapy. Subjects will be randomly assigned to
receive a single intravenous (IV) infusion of one of four dose levels of
CCR5mAb004 or matching placebo. A minimum of 10 subjects will be randomized
to each cohort at a ratio of 4:1 (active:placebo). A minimum of 40 and
maximum of 60 subjects will be enrolled. This study will be conducted at up
to 10 sites in the United States.
http://clinicaltrials.gov/ct/show/NCT00114699;jsessionid=EBDCC037D288A9314B0
95FA5761D487F?order=5

---------------------------------------------------------------------
Drug: TMC114                  ClinicalTrials.gov Identifier:  NCT00115050

TMC114 with Low Dose Ritonavir (RTV) and Other Antiretrovirals in
Experienced HIV-1 Infected Patients with Limited or no Treatment Options
This study is currently recruiting patients.

This is an open-label safety study to provide early access to TMC114 for
HIV-1 infected patients who have failed and exhausted regimens based on
commercially available antiretroviral (ARV) therapy and who are ineligible
for participation in any other Tibotec-sponsored trial.

http://clinicaltrials.gov/ct/show/NCT00115050;jsessionid=EBDCC037D288A9314B0
95FA5761D487F?order=6